Johnny Skillicorn-Aston

4 POSTS 0 COMMENTS
Johnny Skillicorn-Aston is Communications and Engagement Director at Conclusio. He is a communication specialist with over 25 years’ experience in the industry. He leads on this at Conclusio and has supported large-scale transformation projects within the NHS and Pharma, working with both health providers and commissioners, designing communication plans and campaigns to drive effective relationship management within health and social care systems. He has influenced, developed and delivered public consultation methodologies within NHS primary care, pharmacy, integrated care systems and urgent care.

Latest articles

Sanofi’s avalglucosidase alfa receives Promising Innovative Medicine designation

Sanofi’s avalglucosidase alfa receives Promising Innovative Medicine designation

Sanofi has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a Promising Innovative Medicine (PIM) designation for avalglucosidase alfa...
Current trends in compliance

Current trends in compliance

The COVID-19 pandemic has taught us many lessons, but are we missing an age-old one that we all need to learn and act upon?...
LEO Pharma appoints new People Director

LEO Pharma appoints new People Director

Specialist dermatology company, LEO Pharma UK/Ireland, has appointed a new People Director for its North Europe ‘cluster’ countries. Julie Watret joins from Network Rail,...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
LEO Pharma appoints new People Director

LEO Pharma appoints new People Director

Specialist dermatology company, LEO Pharma UK/Ireland, has appointed a new People Director for its North Europe ‘cluster’ countries. Julie Watret joins from Network Rail,...
JYSELECA has received authorisation from the European Commission (EC) for treatment of rheumatoid arthritis

JYSELECA®▼(filgotinib) receives authorisation as treatment for rheumatoid arthritis

It has been announced that JYSELECA®▼(filgotinib), an oral JAK inhibitor, has received marketing authorisation from the European Commission (EC) for the treatment of moderate...
Image of a hand holding a torch to show Kate Bingham appointed Chair of UK Vaccine Taskforce

Kate Bingham appointed Chair of UK Vaccine Taskforce

Kate Bingham has been appointed Chair of the UK’s Vaccine Taskforce – the group set up by the Government’s Chief Scientific Adviser, Deputy Chief...
Image of a lightbulb emerging from a box to show It's all in the mind(set): digital transformation in pharma

It’s all in the mind(set): digital transformation in pharma

The importance of mindset and company culture to enable digital transformation in pharma. Top 5 Takeaways Start with defining and understanding the traditional roadblocks of...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription